Disc Medicine, Inc. Common Stock IRON

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

• GlobeNewswire Inc. 22 sept

  Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.

  

• GlobeNewswire Inc. 12 sept

  Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.

  

• GlobeNewswire Inc. 4 sept

  Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. Rosen Law Firm is investigating potential securities fraud claims and preparing a class action lawsuit on behalf of affected shareholders.

  

• GlobeNewswire Inc. 2 sept

  Disc Medicine to Participate in Upcoming Investor Conferences

  Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on hematologic diseases, announced participation in four major investor conferences in September 2026. The company also reported completing a Type A FDA meeting on bitopertin with Phase 3 APOLLO study data expected in Q4 2026, which could serve as the basis for a Complete Response Letter (CRL) response.

  

• GlobeNewswire Inc. 31 ago

  Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

  Disc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.